0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters to the Editor |

Very High Cytochrome P4501A2 Activity and Nonresponse to Clozapine

S. Bender, MD; C. B. Eap, PhD
Arch Gen Psychiatry. 1998;55(11):1048-1050. doi:.
Text Size: A A A
Published online

Extract

Clozapine is an efficient atypical antipsychotic drug mostly devoid of extrapyramidal adverse effects, with a response rate of about 60% in those with no or partial response to classical neuroleptics.1 Recent studies have suggested optimum clozapine plasma levels in treatment-resistant schizophrenia to be at least 350 ng/mL (3 trials), at least 370 ng/mL (1 trial) and at least 420 ng/mL (1 trial).1 However, considerable interindividual variations of clozapine plasma levels were found for a given dose, depending on factors such as age, sex, and smoking.1 Recently, it has been shown that the addition of selective serotonin reuptake inhibitors such as fluvoxamine improves the efficacy of clozapine in clozapine-resistant schizophrenia.2,3 These improvements can be explained either by pharmacokinetic (increase of clozapine blood concentrations by fluvoxamine) or pharmacodynamic (treatment of negative symptoms by fluvoxamine) effects, but the latter mechanism has been considered the likeliest.2,3 The hypothesis of a very rapid metabolism of clozapine in some nonresponders has never, to our knowledge, been stated or demonstrated.

Figures in this Article

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption

Plasma levels of clozapine, paraxanthine-caffeine ratios, medication, and psychopathology in the course of treatment for patient 1. CGI indicates Clinical Global Impression Scale; PANSS, Positive and Negative Syndrome Scale.

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();